Baroda BNP Paribas Value Fund
The scheme seeks to generate long-term capital appreciation from a diversified portfolio of predominantly equity and equity related instruments by following a value investment strategy.
Growthvine rating: 2/5 — ranked #19 of 25 in category.
Fund basics
| Category | Equity: Value |
|---|
| NAV | ₹13.91 (as of 2026-11-13) |
|---|
| AUM | ₹920 Cr |
|---|
| Expense ratio | 1.92% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ankeet Pandya |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Sharpe ratio | 0.17 |
|---|
| Standard deviation | 15.40% |
|---|
| Max drawdown | −20.14% |
|---|
| Alpha | -2.28 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 92.2% of Nifty 500's upside and 103.2% of its downside.
Market cap allocation
| Large cap | 68.8% |
|---|
| Mid cap | 18.6% |
|---|
| Small cap | 12.7% |
|---|
Concentration
| Top 5 holdings | 24.5% |
|---|
| Top 10 holdings | 39.5% |
|---|
| Total holdings | 52 |
|---|
| Index overlap | 38.2% |
|---|
| Active share | 61.8% |
|---|
Top holdings
- HDFC Bank Ltd. — 5.4%
- Reliance Industries Ltd — 5.2%
- ICICI Bank Ltd. — 5.2%
- Divis Laboratories Ltd. — 4.4%
- Bharat Heavy Electricals Ltd. — 4.3%
- Larsen & Toubro Limited — 4.1%
- Infosys Ltd — 3.0%
- Sun Pharmaceutical Industries Ltd. — 2.7%
- Torrent Pharmaceuticals Ltd. — 2.6%
- Clearing Corporation of India Ltd — 2.6%
Top sectors
- Banking & Financial — 18.1%
- Pharma & Biotech — 13.8%
- Automobile — 8.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −2.1% | Q3 | #15 of 23 |
| 2025 | 1.8% | Q4 (Bottom) | #19 of 22 |
| 2024 | 14.8% | Q4 (Bottom) | #19 of 21 |